Inhibitory immunologicznych punktów kontrolnych podziału komórki w leczeniu chorób nowotworowych

Publication date: Available online 25 April 2016 Source:Acta Haematologica Polonica Author(s): Aleksandra Mędra, Agata Majchrzak, Piotr Smolewski Despite of great progress in anti-neoplastic treatment several solid tumors and hematologic malignancies still remain incurable. Immune system remains under control of several controlling mechanisms. Genetic or epigenetic changes in neoplastic cells provide antigen-derived diversity; however, these cells do not initiate immune response. The main mechanism of development of immune resistance by tumor cells seems to be a change in expression of proteins engaged in the immune control point. Immunotherapy with immune checkpoint inhibitors has emerged as promising modality of tumors showing response to several antigens, e.g. anti-CTLA-4 or PD1-PDL1 monoclonal antibodies. In this review we demonstrate the state in the field on this modality of anti-neoplastic treatment.
Source: Acta Haematologica Polonica - Category: Hematology Source Type: research